Greater Barcelona Metropolitan Area, December 2024 – Petr Vinduška has been appointed as the Chief Financial Officer (CFO) of AbilityPharma, a clinical-stage biopharmaceutical company pioneering first-in-class therapies in oncology. Based in the Greater Barcelona Metropolitan Area, Petr will oversee the company’s financial strategy and operations, working closely with the leadership team to drive growth and innovation.
Expressing gratitude to the CEO, Carles Domenech, Petr shared, “Together with the entire Ability team, we’re embarking on an exciting journey, and I’m looking forward to tackling the challenges and opportunities that lie ahead.”
Petr joins AbilityPharma with a wealth of experience in finance, strategy, and operations. Prior to this role, he served as Head of Operations at Inveniam Group, where he led strategic planning, process optimization, and cross-functional collaboration while overseeing financial operations and resource allocation.
Earlier, Petr was the Interim General Manager at ELIS, where he successfully integrated the acquired PEVI, s.r.o. into the international group, harmonizing operations and implementing standardized reporting systems. He also spent a decade with PEVI, s.r.o., holding roles such as Managing Director and Financial Director, during which he drove financial growth, digital transformation, and strategic investments, preparing the company for a successful sale.
About AbilityPharma
AbilityPharma is a clinical-stage biopharmaceutical company committed to developing innovative therapies addressing unmet medical needs in oncology. Its lead asset, ABTL0812, is undergoing a phase 2b clinical trial for metastatic pancreatic cancer, with previous successful trials in endometrial cancer and squamous NSCLC.
The company’s groundbreaking approach focuses on unique mechanisms of action, combining autophagy induction, ER stress, and immunomodulatory effects, with potential applications across multiple cancer types. Recognized with Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, AbilityPharma is at the forefront of cancer therapeutics innovation.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
